Company Overview and News

0
Yuan at 7 per US dollar? No time soon, say China watchers

2018-08-08 malaymail
SHANGHAI, Aug 8 — The dramatic decline in China’s currency is about to decelerate, according to the respondents in a Bloomberg survey.
CRZBY 3968 STAN CRZBF 580001 STAB STAN STAC 2888 SCBFF BVA O39

0
The Yuan at 7 Per Dollar? No Time Soon, Say China Watchers - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CRZBY 3968 STAN CRZBF 580001 STAB STAN STAC 2888 SCBFF BVA O39

0
PBOC to Remove Reserve Requirement on FX Forward Trading - Bloomberg

2018-08-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
3968

0
With tariffs imminent, Chinese stocks and currency slip

2018-07-06 theedgemarkets
SHANGHAI (July 6): Chinese stocks and the yuan slipped on Friday morning ahead of the implementation of major tariffs that will significantly shift the U.S.-China trade row to a new level and cloud the global economic outlook.
3968

4
China stocks, yuan dip ahead of tariff trigger

2018-07-06 thehindubusinessline
A man looks at a monitor showing stock information at a brokerage house in Fuyang, Anhui province, China. - Reuters
3968 500570 TATAMOTORS TTM

0
Yuan slips to six-month low, outlook bearish amid trade friction

2018-06-27 malaymail
SHANGHAI, June 27 — China’s yuan weakened beyond a psychologically key 6.6 per dollar level for the first time in six months today, and though it recouped some of the losses by midday bets are growing for further downside amid an escalating Sino-US trade row.
3968

0
Chinese facial recognition start-up Megvii makes push into Southeast Asia

2018-06-25 theedgemarkets
(June 25): Megvii, the Beijing-based facial recognition start-up whose technology has been used by police departments to arrest fugitives, is seeking to expand its presence in Southeast Asia as China bolsters its export of surveillance and security technology.
CHCJY 3968 LNVGF LNVGY CHBJF 0992

0
Co-working space operator Soho China targets Hong Kong IPO next year as it expands in the mainland

2018-06-20 scmp
Soho China, one of the country’s largest commercial property companies, aims to list its co-working space business in Hong Kong next year, according to its chairman Pan Shiyi.
SOHOF 3968 0410

2
JP Morgan’s top-performing fund manager counts on China’s youngster to defend her title

2018-06-14 scmp
The firm’s China Fund has delivered a 38pc return over the past year, thanks to gains from China’s online entertainment and private school stocks
3968 CHN

15
Xiaomi to be the first target of China’s unicorn funds, giving mainland investors a taste of marquee IPOs

2018-06-07 scmp
Six of the first funds will have a combined war chest of 300 billion yuan, more than the sum total of every A-share IPO last year, enough for them to act as cornerstone investors in the biggest blockbuster stock offers
CICHY 0941 3968 CHLKF CHL CICHF CCB 0939

1
China funds to boost support for domestic listings of tech giants: Report

2018-06-06 channelnewsasia
Six Chinese mutual funds will be launched as early as next Monday, potentially channeling hundreds of billions of yuan from investors into domestic floatations of overseas-listed Chinese tech giants, the Shanghai Securities News reported on Wednesday.
CICHY 3968 CICHF CCB 0939

1
China funds to boost support for domestic listings of tech giants - paper

2018-06-06 channelnewsasia
Six Chinese mutual funds will be launched as early as next Monday, potentially channeling hundreds of billions of yuan from investors into domestic floatations of overseas-listed Chinese tech giants, the Shanghai Securities News reported on Wednesday.
CICHY 3968 CICHF CCB 0939

79
China funds to boost support for domestic listings of tech giants - paper

2018-06-06 reuters
SHANGHAI (Reuters) - Six Chinese mutual funds will be launched as early as next Monday, potentially channeling hundreds of billions of yuan from investors into domestic floatations of overseas-listed Chinese tech giants, the Shanghai Securities News reported on Wednesday.
CICHY 3968 BABA CICHF CCB 0939

0
Chinese banks in push to spin-off asset management units

2018-06-03 scmp
Banks in China are vying to set up independent asset management subsidiaries to cope with tighter regulations on wealth management that aim to break implicit guarantees of banking products worth 30 trillion yuan (US$4.7 trillion).
3968

2
Anbang’s Long, Slow Road to Redemption - Bloomberg

2018-05-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CGMBF 3968 2628 UBS LFC CMAKY ULSGF

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...